Convergent Dental, developer of Solea® – the world’s first laser to enable reliably anaesthesia-free, pain-free dentistry, has completed a US$40M Series C funding round. The investment is led by Arboretum Ventures, with participation from existing investors, including Long River Ventures and the Gund Foundation.
Solea is the leading all-tissue laser in dentistry. This breakthrough technology enables virtually any cavity to be treated without anaesthesia, and soft tissue surgeries to be completed with little to no anaesthesia, bleeding or sutures. In addition, Convergent Dental recently launched Solea Sleep, a painless, non-surgical treatment for snoring that works by tightening tissue in the soft palate in a simple five-minute treatment. Dentists who use Solea experience significant practice growth as a result of the drill-free, needle-free patient experience and the new procedures that they can perform.
“We are excited to have completed this round of funding,” said Michael Cataldo, chief executive officer of Convergent Dental. “It will enable us to drive even more growth by expanding our product portfolio and increasing our investment in market development.”
The lead investor, Arboretum Ventures, specialises in the healthcare sector, investing in companies that improve patient outcomes and reduce healthcare costs. Solea is a perfect fit. Convergent Dental will invest funds from this round to accelerate the development of new product capabilities and bolster its already strong sales performance.
“Convergent is on its way to revolutionising general dentistry, moving beyond ‘the needle and the drill’ to a much-improved patient experience. We are very excited to be part of the journey,” said Tim Petersen, founder and managing partner of Arboretum Ventures.
